What are the recommended 4‑month treatment regimens for an adult with newly diagnosed drug‑susceptible pulmonary tuberculosis who has normal liver function, is not pregnant, has no fluoroquinolone allergy, and is not HIV‑positive?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

4-Month Rifapentine-Moxifloxacin Regimen for Drug-Susceptible TB

For adults aged ≥12 years with newly diagnosed drug-susceptible pulmonary tuberculosis who meet eligibility criteria, use the 4-month rifapentine-moxifloxacin regimen (4-HPMZ): 8 weeks of daily rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by 9 weeks of daily rifapentine, isoniazid, and moxifloxacin (total 119 doses within 5 months). 1, 2

Regimen Structure

The 4-month daily treatment consists of:

Intensive Phase (8 weeks/56 doses):

  • Rifapentine (RPT)
  • Isoniazid (INH)
  • Pyrazinamide (PZA)
  • Moxifloxacin (MOX)

Continuation Phase (9 weeks/63 doses):

  • Rifapentine (RPT)
  • Isoniazid (INH)
  • Moxifloxacin (MOX)

The intensive phase must be completed within 70 days of treatment initiation, and continuation phase within 84 days of intensive phase completion, for total completion within 5 months 1.

Patient Eligibility Criteria

You can use this regimen if the patient:

  • Is aged ≥12 years
  • Has drug-susceptible pulmonary TB (confirmed by molecular and phenotypic testing)
  • Has normal liver function (ALT/AST <3x upper limit normal, bilirubin <2.5x upper limit normal)
  • Has normal renal function (creatinine <2x upper limit normal)
  • Has normal potassium (≥3.5 mEq/L)
  • Is not pregnant
  • Is HIV-negative OR HIV-positive with CD4 count ≥100 cells/mm³ 1, 3
  • Has no fluoroquinolone allergy
  • Has no preexisting advanced liver disease or end-stage renal disease

Critical exclusion: This regimen was not studied in HIV-positive patients with CD4 counts <100 cells/mm³, and should not be used in this population 3.

Key Monitoring Requirements

The 2022 CDC guidance provides specific monitoring schedules 1:

Baseline assessments:

  • Sputum for rapid molecular testing (resistance to INH, PZA, RIF, fluoroquinolones)
  • Sputum AFB smear and culture
  • Phenotypic drug susceptibility testing (must include rifapentine, INH, PZA, moxifloxacin)
  • Chest radiograph
  • Comprehensive metabolic panel (ALT, AST, bilirubin, alkaline phosphatase, creatinine)
  • Electrolytes (potassium, calcium, magnesium)
  • Platelet count
  • HIV testing

Monthly monitoring during treatment:

  • Sputum AFB smear and culture until two consecutive negatives
  • Weight assessment
  • Symptom review and adverse event monitoring
  • Laboratory testing (liver function, platelets, creatinine, electrolytes) at weeks 4,8,12, and 16

Evidence Quality and Strength

The most recent 2025 ATS/CDC/ERS/IDSA guidelines provide a strong recommendation for this regimen based on clinical trial data demonstrating non-inferiority to the standard 6-month regimen 2. The 2022 CDC interim guidance established the framework for implementation in the United States 1.

Important Clinical Caveats

Real-world implementation challenges exist: A 2025 study from NYC Health Department TB clinics found that among 284 eligible patients, only 40 (14%) were prescribed 4-HPMZ, with just 36% completing treatment. The primary reason for discontinuation was adverse events (42% of those who started) 4. This highlights the importance of:

  • Careful patient selection
  • Intensive monitoring for adverse events
  • Having contingency plans for regimen modification
  • Ensuring rifapentine availability (a known barrier) 5

Drug interactions matter: Moxifloxacin can prolong QT interval. Rifapentine has significant drug interactions, particularly with antiretrovirals, which is why careful consideration is needed in HIV-positive patients 5.

Alternative for paucibacillary disease: The 4-month regimen may also be used for smear-negative, culture-negative, noncavitary TB, though this was not specifically studied in the pivotal trial 1.

When NOT to Use This Regimen

Switch to standard 6-month therapy or individualized longer regimens if:

  • Extrapulmonary TB (except pleural or lymph node TB)
  • Drug resistance detected to any component
  • Severe hepatic or renal dysfunction develops
  • Intolerable adverse events occur
  • HIV-positive with CD4 <100 cells/mm³
  • Pregnancy occurs during treatment
  • Patient unable to complete within the specified timeframe

The evidence strongly supports this regimen as equally effective as 6-month therapy with the advantage of shorter duration, but successful implementation requires rigorous patient selection, monitoring infrastructure, and management of adverse events 1, 2.

References

Research

HIV-Associated Tuberculosis in Adults: Diagnosis and Clinical Management.

Cold Spring Harbor perspectives in medicine, 2026

Research

Challenges to initiate and complete a 4-month rifapentine-moxifloxacin TB treatment regimen.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.